XIAP discriminates between type I and type II FAS-induced apoptosis
- Jost, PJ; Grabow, S; Gray, D; McKenzie, MD; Nachbur, U; Huang, DCS; Bouillet, P; Thomas, HE; Borner, C; Silke, J; Strasser, A; Kaufmann, T;
Publication Year 2009-08-20, Volume 460, Issue #7258, Page 1035-U128
- Journal Title
- Publication Type
- Journal Article
- FAS (also called APO-1 and CD95) and its physiological ligand, FASL, regulate apoptosis of unwanted or dangerous cells, functioning as a guardian against autoimmunity and cancer development(1-4). Distinct cell types differ in the mechanisms by which the 'death receptor' FAS triggers their apoptosis(1-4). In type I cells, such as lymphocytes, activation of 'effector caspases' by FAS-induced activation of caspase-8 suffices for cell killing, whereas in type II cells, including hepatocytes and pancreatic beta-cells, caspase cascade amplification through caspase-8-mediated activation of the proapoptotic BCL-2 family member BID (BH3 interacting domain death agonist) 5 is essential(6-8). Here we show that loss of XIAP (X-chromosome linked inhibitor of apoptosis protein) 9,10 function by gene targeting or treatment with a second mitochondria-derived activator of caspases (SMAC(11,) also called DIABLO(12); direct IAP-binding protein with low pI) mimetic drug in mice rendered hepatocytes and beta-cells independent of BID for FAS-induced apoptosis. These results show that XIAP is the critical discriminator between type I and type II apoptosis signalling and suggest that IAP inhibitors should be used with caution in cancer patients with underlying liver conditions.
- NATURE PUBLISHING GROUP
- ALPHA-DEPENDENT APOPTOSIS; DEFICIENT MICE; IMMUNE-SYSTEM; T-LYMPHOCYTES; CYTOCHROME-C; CELL-DEATH; PROTEIN; SMAC; ACTIVATION; RECEPTOR
- Publisher's Version
- Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2009-08-20 12:00:00Last Modified: 0001-01-01 12:00:00